This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Around the world, most people are regularly exposed to low or moderate levels of lead, cadmium and arsenic in the environment, increasing risk of coronaryarterydisease, stroke and peripheralarterydisease, according to a new statement.
Background and aims In the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovasculardiseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. 3.95, p = 0.003). 3.95, p = 0.003). vs. 45.8%; 17.6% vs. 13.9%, p = 0.001).
Atherosclerosis is characterized by a narrowing of arterial walls and can increase risk of coronaryarterydisease, stroke, peripheralarterydisease, or kidney disorders.
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronaryarterydisease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
Background and aims Epidemiology of atherosclerotic cardiovasculardisease might be different in patients with polygenic hypercholesterolemia plus high levels (≥30 mg/dl) of Lp(a) (H-Lpa) than in those with polygenic hypercholesterolemia alone (H-LDL).
Objective Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovasculardisease (CVD). Eligible and ineligible patients were compared on baseline characteristics, cardiovascular events, major bleeding and mortality.
Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronaryarterydisease, large artery atherosclerotic stroke, and peripheralarterydisease.
Six multimorbidity patterns were identified, including 4 specific patterns: (1) pattern 1, cerebrovascular cluster (histories of cerebrovascular disease and hypertension); (2) pattern 2, traditional cardiovasculardisease risk factors cluster (histories of hyperlipidemia, obesity, anddiabetes, and family history of cardiovasculardisease and smoking); (..)
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheralarterydisease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with PeripheralArteryDisease (PAD).
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 24,25 Among statin-treated patients with hsCRP greater than 2 mg/L, risks for cardiovascular death were high regardless of LDL-C level.21 4 In the U.S.
Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovasculardisease, one of the leading causes of death globally.
Methods This narrative review examines the contemporary literature assessing intermediate- and long-term event rates in patients with established CV disease treated with statins. Repeat revascularization and CV-related death occurs in up to 38% and 33% of patients with peripheralarterydisease after three years, respectively.
In congenital heart diseases, SDoHs can affect major outcomes, as well. In conclusion, SDoHs significantly impact cardiovascular morbidity and death and specific outcomes of patients with cardiovasculardisease.
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronaryarterydisease (CAD) and peripheralarterydisease (PAD).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content